Androgen ablation augments human HLA2.1‐restricted T cell responses to PSA self‐antigen in transgenic mice

Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer

2006 • 1,069 citations

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

2010 • 947 citations

Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer

2008 • 680 citations

Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance

2004 • 576 citations

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

2002 • 491 citations

Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

1999 • 468 citations

Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors

2002 • 424 citations

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

1997 • 383 citations

T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer

2001 • 373 citations

Cancer immunotherapy with mRNA‐transfected dendritic cells

2004 • 307 citations

A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

2000 • 300 citations

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

2006 • 291 citations

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen

2005 • 279 citations

In Vitro Generation of Human Cytotoxic T Lymphocytes Specific for Peptides Derived From Prostate-Specific Antigen

1997 • 267 citations

The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice.

1994 • 259 citations

Augmentation of T Cell Levels and Responses Induced by Androgen Deprivation

2004 • 258 citations

Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology Group

2004 • 252 citations

Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer

1999 • 206 citations

A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer

2004 • 191 citations

A recombinant vaccinia virus expressing human prostate‐specific antigen (PSA): Safety and immunogenicity in a non‐human primate

1995 • 109 citations

Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate‐pulsed cells: a phase I/II study

2004 • 109 citations

Induction of cellular and humoral immune responses to tumor cells and peptides in HLA‐A24 positive hormone‐refractory prostate cancer patients by peptide vaccination

2003 • 105 citations

The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue.

1994 • 105 citations

The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice

1994 • 102 citations

Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization

2009 • 95 citations

Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen

1995 • 87 citations

Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine

1998 • 85 citations

Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.

2002 • 79 citations

Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA

2004 • 79 citations

Update on anti-CTLA-4 antibodies in clinical trials

2007 • 73 citations

Early castration reduces prostatic carcinogenesis in transgenic mice

1999 • 69 citations

Construction and Characterization of an Attenuated Listeria monocytogenes Strain for Clinical Use in Cancer Immunotherapy

2008 • 63 citations

Immunotherapy of patients with hormone‐refractory prostate carcinoma pre‐treated with interferon‐gamma and vaccinated with autologous PSA‐peptide loaded dendritic cells—A pilot study

2007 • 56 citations

Induction of PSA‐specific CTLs and anti‐tumor immunity by a genetic prostate cancer vaccine

2004 • 52 citations

Dehydroepiandrosterone replacement in patients with Addison's disease has a bimodal effect on regulatory (CD4⁺CD25^hi and CD4⁺FoxP3⁺) T cells

2005 • 49 citations

Cytotoxic T Lymphocyte Escape Variants, Induced Mutations, and Synthetic Peptides Define a Dominant H-2Kb-Restricted Determinant in Simian Virus 40 Tumor Antigen

1995 • 43 citations

Induction of Tumor Antigen-Specific Immunity In Vivo by a Novel Vaccinia Vector Encoding Safety-Modified Simian Virus 40 T Antigen

1999 • 35 citations

Technology Insight: vaccine therapy for prostate cancer

2005 • 23 citations

Induction of Th1-type immunity and tumor protection with a prostate-specific antigen DNA vaccine

2005 • 22 citations

Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer

2008 • 4 citations

A safety-modified SV40 Tag developed for human cancer immunotherapy.

2009 • 1 citations

Cited By (0)

No citing papers found in database